Edition:
India

Impax Laboratories Inc (IPXL.OQ)

IPXL.OQ on NASDAQ Stock Exchange Global Select Market

17.00USD
8 Dec 2017
Change (% chg)

-- (--)
Prev Close
$17.00
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
346,094
52-wk High
$25.70
52-wk Low
$7.80

Chart for

About

Impax Laboratories, Inc. is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma. The Impax... (more)

Overall

Beta: 1.03
Market Cap(Mil.): $1,620.01
Shares Outstanding(Mil.): 74.31
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.14 16.44
EPS (TTM): -- -- --
ROI: -- 14.86 10.62
ROE: -- 16.28 14.20

BRIEF-Impax Receives Tentative fda Approval Of Generic Coreg CR (Carvedilol Phosphate) Extended-Release Capsules

* IMPAX RECEIVES TENTATIVE FDA APPROVAL OF GENERIC COREG CR® (CARVEDILOL PHOSPHATE) EXTENDED-RELEASE CAPSULES

08 Dec 2017

BRIEF-Impax Laboratories says co entered into amendment no. 1 to business combination agreement with Atlas Holdings ​

* Impax Laboratories Inc - ‍on Nov 21, co entered into amendment no. 1 to business combination agreement, dated October 17, 2017 with Atlas Holdings ​

22 Nov 2017

BRIEF-Impax Laboratories says board of co amended and restated bylaws of co

* Impax Laboratories says ‍on and effective Nov 10, 2017, board of co amended and restated bylaws of company - SEC filing

14 Nov 2017

BRIEF-Impax Q3 adjusted earnings per share $0.23

* Q3 earnings per share view $0.20 -- Thomson Reuters I/B/E/S

09 Nov 2017

BRIEF-Impax gets FDA approval for generic Renvela tablets

* Impax announces FDA approval and launch of generic Renvela (sevelamer carbonate) tablets, 800 mg

24 Oct 2017

UPDATE 3-Amneal, Impax combine to tackle generic drug pricing pressure

* Impax was expected to keep >25 pct stake - analyst (Adds analysts' comments, background on retail pharmacies; updates shares)

17 Oct 2017

BRIEF-IMPAX TO PAY AMNEAL $45 MLN IF DEAL TERMINATED UNDER CERTAIN CIRCUMSTANCES‍​

* REQUIRED TO PAY AMNEAL FEE OF $45 MILLION IF DEAL TERMINATED UNDER CERTAIN CIRCUMSTANCES‍​

17 Oct 2017

Drugmakers Amneal, Impax to combine in generics push

Amneal Pharmaceuticals LLC is buying peer Impax Laboratories Inc in an all-stock deal as it looks to add heft to its generics business and gain an edge in a tough drug pricing environment.

17 Oct 2017

BRIEF-Drugmaker Amneal to combine with Impax Labs

* Transaction expected to generate $200 million of annual cost savings within three years​

17 Oct 2017

Drugmakers Amneal and Impax to combine

Oct 17 Privately-held generic drugmaker Amneal Pharmaceuticals LLC and peer Impax Laboratories Inc said on Tuesday they would combine in an all-stock transaction.

17 Oct 2017

Earnings vs. Estimates